Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2248761 + lopinavir + ritonavir
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a combination of **GSK2248761** (formerly IDX899), a next-generation, once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI), with **lopinavir** and **ritonavir**, both HIV-1 protease inhibitors. GSK2248761 displayed potent activity against wild-type and efavirenz-resistant HIV-1 strains, but development was discontinued due to safety concerns, specifically seizure events[2][4]. Lopinavir/ritonavir is a well-established fixed-dose antiretroviral regimen where ritonavir boosts plasma levels of lopinavir by inhibiting CYP3A4-mediated metabolism; this combination is marketed as Kaletra[3][7]. The triple combination was studied for drug-drug interactions in HIV-1 treatment, with data showing potential PK interactions but not marketed as a single product[1].
- Brand names
- Kaletra
- Other names
- lopinavir/ritonavir
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseCYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)
Beyond the preview
Go deeper on GSK2248761 + lopinavir + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2248761 + lopinavir + ritonavir.